UK skull-base neurosurgery · Patient guide
Endoscopic pituitary tumour surgery, through the nose, by a joint UK skull-base team.
A patient guide to the modern gold-standard operation for pituitary adenoma — four-handed endoscopic endonasal transsphenoidal resection, delivered by a joint neurosurgery-ENT team inside a UK pituitary MDT.
Why patients choose us
- 01
A pituitary MDT, not a solo surgeon
Endocrinologist, neurosurgeon, ENT skull-base surgeon, neuro-ophthalmologist and neuroradiologist — every case reviewed together before a knife is picked up.
- 02
Four-handed endoscopic technique
Neurosurgeon and ENT skull-base surgeon in theatre together — the modern standard the Society of British Neurological Surgeons and ENT-UK now expect.
- 03
Independent, and free
We are paid by no hospital, so the recommendation is impartial and costs you nothing.
Indicative pricing
What private pituitary tumour surgery costs in the UK.
Indicative ranges across UK skull-base teams. Send the imaging and the bloods and we quote firm figures across two or three MDT-led options.
In short
A non-functioning macroadenoma resection in our network: £24,000–£38,000, home in 3–5 days.
| Procedure | Indicative range | Typical duration | Recovery |
|---|---|---|---|
| Endoscopic transsphenoidal resection — non-functioning macroadenoma | £24,000–£38,000 | 2–3 hr GA | 3–5 day stay |
| Endoscopic transsphenoidal resection — acromegaly (GH) | £26,000–£42,000 | 2–3 hr GA | 3–5 day stay |
| Endoscopic transsphenoidal resection — Cushing’s disease (ACTH) | £28,000–£45,000 | 2.5–3.5 hr | 4–6 day stay |
| Endoscopic transsphenoidal resection — prolactinoma (DA-failed) | £25,000–£40,000 | 2–3 hr GA | 3–5 day stay |
| Pituitary apoplexy — urgent decompression | £28,000–£48,000 | Same-day | 5–10 day stay |
| Neurosurgical consultation only | £350–£600 | 45 min | Same visit |
Prices vary by hospital, by the joint neurosurgery-ENT team, by tumour subtype, and by whether adjuvant stereotactic radiotherapy or long-term endocrine follow-up is included. We come back with firm quotes within a few working days.
The problem
The right MDT, the right team, the right tumour.
Pituitary surgery volume is what drives outcomes. UK skull-base guidance is clear — high-volume, MDT-led, joint neurosurgery-ENT teams. Booked outside that model, the same tumour has a very different result.
-
Not sure it is really surgical?
Some tumours — most prolactinomas, many microadenomas — are best left alone or managed medically. The MDT decides that before you agree to theatre.
-
Worried about hormone loss?
A named endocrinologist plans your workup and long-term follow-up. Replacement, where needed, is straightforward and lifelong.
-
Want it done properly?
A named consultant neurosurgeon, a joint ENT skull-base surgeon in the same theatre, and a pituitary MDT that reviews every case before and after.
The journey
From MRI to hormone follow-up — what happens, in order.
One MDT from first review to long-term endocrine follow-up — including the delayed sodium check that many patients only learn about after the fact.
Phase 1 · Before your procedure
MDT workup and pre-op tests
Phase 2 · On the day
Admission, theatre and ward
Phase 3 · After
Hormones, ENT, MRI
- 01
Before
You send us the imaging and bloods
A short, confidential form plus any pituitary MRI, visual field test and endocrine bloods you already have.
- 02
Before
MDT review and shortlist
Within a few working days: two or three joint neurosurgery-ENT teams matched to your tumour type, an indicative price, and a plan for any missing tests.
- 03
Before
Pre-op workup completed
Dedicated pituitary MRI, formal visual fields, and a full dynamic pituitary hormone panel — 9am cortisol, IGF-1, prolactin, TSH/T4, LH/FSH, testosterone or oestradiol, and an overnight dexamethasone test if Cushing’s is suspected.
- 04
On the day
Admission and consent
You are admitted the morning of surgery. Named neurosurgeon, ENT skull-base surgeon and anaesthetist all meet you before theatre.
- 05
On the day
The operation itself
Two to three hours under GA. Four-handed endoscopic endonasal transsphenoidal approach: through the nose, into the sphenoid sinus, sella opened, adenoma resected, floor reconstructed — with a nasoseptal flap if there is a high-flow CSF leak.
- 06
On the day
Recovery and ward
A few hours in recovery with hourly fluid balance and urine output, then to a neurosurgical bed. Three to five days in hospital is typical.
- 07
After
Follow-up and hormones
ENT nasal check at six weeks. Repeat pituitary hormones at six weeks and three months. Sodium checked between day five and day eight to catch delayed SIADH. Post-op MRI at three months.
Typical end-to-end: 3–6 weeks from imaging review to surgery. Full endocrine review: 3 months.
When it helps
When endoscopic pituitary surgery is the right step.
The tumour types and clinical situations we see most, plus the one red flag that means an emergency rather than an appointment.
-
Non-functioning macroadenoma with mass effect
A tumour large enough to press on the optic chiasm — bitemporal visual field loss, or new hypopituitarism on bloods.
-
Acromegaly (GH-secreting)
Raised IGF-1 and a failed glucose-suppression GH test. Surgery is first-line for most GH-secreting adenomas.
-
Cushing’s disease (ACTH-secreting)
Biochemically confirmed ACTH-dependent Cushing’s with a pituitary source on MRI or petrosal sinus sampling — surgery is first-line.
-
Prolactinoma intolerant of medical therapy
Reserved for patients who fail or cannot tolerate dopamine agonists (cabergoline, bromocriptine) — most prolactinomas are still managed medically.
-
TSH-secreting adenoma (TSHoma)
Rare, but surgery is the definitive treatment for these central hyperthyroidism tumours.
-
Progressive visual field loss
A shrinking bitemporal hemianopia on repeat perimetry is a clear indication to operate, regardless of tumour type.
-
Cystic or apoplectic change
Sudden headache, ophthalmoplegia and visual loss from bleeding into the tumour — pituitary apoplexy is a neurosurgical emergency.
-
Red flag: sudden vision loss + headache
Acute severe headache with new visual or eye-movement loss needs same-day A&E, not a clinic booking — this is apoplexy until proven otherwise.
Procedure options
Endoscopic transsphenoidal is not the only route.
What each option actually involves — and which fits which tumour type and clinical picture.
-
Endoscopic endonasal transsphenoidal (EETS)
The modern gold-standard approach. Rigid endoscope through the nose and sphenoid sinus to the sella. Panoramic view, no facial incision.
-
Four-handed neurosurgery + ENT technique
Neurosurgeon and ENT skull-base surgeon operate together — one drives the endoscope, one operates. Now standard in UK skull-base units.
-
Extended endoscopic approach
For tumours extending above or lateral to the sella — the bony opening is extended into the planum sphenoidale or clival recess.
-
Microscopic transsphenoidal (legacy)
The older speculum-and-microscope technique. Still used in a few UK centres, but the endoscope has largely replaced it.
-
Craniotomy (transcranial)
Reserved for very large, dumbbell-shaped or laterally extending tumours where the nose cannot reach — a minority of cases.
-
Stereotactic radiotherapy (adjuvant)
Gamma Knife or CyberKnife to residual or recurrent tumour after surgery — usually delivered by a clinical oncologist in a dedicated unit.
-
Medical therapy alone (prolactinoma)
For most prolactinomas, cabergoline or bromocriptine is first-line and often life-long — surgery is only for intolerance or failure.
-
Watch-and-scan
A small non-functioning microadenoma with normal hormones and no mass effect may safely be monitored with serial MRI.
Our vetted UK network
A small panel of skull-base teams, we picked them.
Joint neurosurgery-ENT skull-base teams in London and across the UK, all operating inside a formal pituitary MDT. Not listed publicly — introductions are private, once we understand your case.
Selection criteria
How we choose every pituitary team in our network.
-
A named consultant neurosurgeon on the Specialist Register with a declared pituitary and skull-base practice
-
A joint ENT skull-base surgeon in theatre — four-handed endoscopic technique as standard
-
A pituitary MDT that meets weekly with endocrinology, neuro-ophthalmology and neuroradiology
-
A named consultant endocrinologist to lead your pre-op workup and long-term hormone follow-up
Safety and recovery
What to expect afterwards — honestly.
Endoscopic transsphenoidal surgery is safe in high-volume UK skull-base hands. The things worth planning for are the fluid balance, the delayed sodium check, and the hydrocortisone cover on discharge.
-
CSF leak — 2 to 5 percent
A hole in the dura that lets brain fluid leak into the nose. Small leaks are sealed at the same operation with a nasoseptal flap; a persistent leak usually needs a lumbar drain or a return to theatre.
-
Diabetes insipidus (DI)
Around 20 percent have transient DI in the first days — large volumes of dilute urine and thirst, managed with desmopressin. Permanent DI settles at 2 to 5 percent.
-
Delayed SIADH — day 5 to 8
A drop in sodium about a week after surgery is common enough that we check your bloods between day five and day eight, even if you feel well.
-
New pituitary hormone loss — 5 to 15 percent
Some pituitary function may be lost. Steroid, thyroid and sex hormone replacement is straightforward when needed — your endocrinologist manages this.
-
Meningitis — under 1 percent
Uncommon, and much reduced with a properly sealed skull base. Fever, neck stiffness or severe headache after discharge is an A&E visit.
-
Carotid or optic injury — very rare
Catastrophic vascular injury sits at well under 1 percent in experienced hands. Post-op visual worsening is rare — most patients see improvement in their fields.
-
Nasal crusting and smell
Expect crusting, blockage and a temporarily reduced sense of smell for six to twelve weeks. Saline douching and ENT review at six weeks help this settle.
-
Hydrocortisone cover post-op
You will be discharged on a stress dose of hydrocortisone until a formal 9am cortisol at six weeks confirms your adrenal axis is intact.
-
Red flags after discharge
Clear watery drip from the nose, severe headache with fever or stiff neck, sudden visual loss, or excessive thirst and urination — call the team or attend A&E the same day.
Reading your operation note
Your operation note in four parts. Read the last one first.
Whichever team operates, the note the neurosurgeon and endocrinologist send you keeps to the same shape.
A quiet reminder
Surgical and endocrine language is precise and can read coldly — we translate it for you.
If you would like us to talk you through the op note or the hormone results before your follow-up, just ask.
- 01 Header
Tumour type, size and MDT decision
Which adenoma (non-functioning, GH, ACTH, prolactin, TSH), its size and extension, and why the pituitary MDT recommended surgery over medical or radiotherapy options.
- 02 Technique
Approach and reconstruction
Four-handed endoscopic endonasal transsphenoidal approach, extent of sella opening, degree of resection (gross-total, near-total or subtotal) and how the skull base was reconstructed.
- 03 Findings
Histology, cavernous sinus, remnant
Immunohistochemistry (which hormone the tumour stained for), whether the cavernous sinus was invaded, and whether any residual tumour was deliberately left.
- 04 Impression
Remission, hormones and follow-up plan
Read this first: expected biochemical remission, your hydrocortisone plan, when hormones and MRI will be rechecked, and whether adjuvant radiotherapy is likely.
Recognised by major UK insurers
Cover for pituitary tumour surgery is usually approved for symptomatic and functioning tumours. We confirm cover — and any excess — with your insurer before booking.
Frequently asked
Everything patients ask about endoscopic pituitary surgery.
Straight answers on the operation, the tests, the hospital stay, the risks and the remission rates.
-
What is endoscopic transsphenoidal pituitary surgery?
It is the modern gold-standard operation to remove a pituitary adenoma. A rigid endoscope is passed through the nose and sphenoid sinus to the sella turcica — the bony pocket that houses the pituitary gland — and the tumour is removed under direct vision. There is no external incision, no shaved head, and no craniotomy.
-
Why is a joint neurosurgery and ENT team used?
Because the nose is ENT territory and the pituitary is neurosurgical territory. UK skull-base units — guided by the Society of British Neurological Surgeons and ENT-UK — now use a four-handed technique with both surgeons in theatre. It gives the best view, the cleanest reconstruction, and the lowest rate of complications.
-
Which pituitary tumours actually need surgery?
Non-functioning macroadenomas that press on the optic chiasm; almost all GH-secreting (acromegaly), ACTH-secreting (Cushing’s disease) and TSH-secreting adenomas; and prolactinomas only when patients cannot tolerate or do not respond to dopamine-agonist tablets. Most prolactinomas are managed medically for life.
-
What are the remission rates?
For non-functioning macroadenomas, gross-total resection is achieved in around 70 to 90 percent when the tumour has not invaded the cavernous sinus. Biochemical remission for acromegaly is 40 to 70 percent depending on size and invasion. Cushing’s disease remission sits at 65 to 85 percent in experienced UK centres.
-
What tests do I need before surgery?
A dedicated pituitary MRI, formal Humphrey visual field testing by a neuro-ophthalmologist, and a full dynamic pituitary hormone panel — 9am cortisol, GH and IGF-1, prolactin, TSH and free T4, LH, FSH and testosterone or oestradiol. If Cushing’s is suspected we add an overnight dexamethasone suppression test and 24-hour urinary free cortisol.
-
How long is the hospital stay?
Three to five days is typical for a straightforward case. You spend the first night on a neurosurgical unit with hourly fluid-balance monitoring to catch diabetes insipidus. Sodium is rechecked between day five and day eight — even after discharge — because delayed low sodium (SIADH) peaks in that window.
-
What are the main risks?
CSF leak in 2 to 5 percent, transient diabetes insipidus in about 20 percent (permanent in 2 to 5 percent), new pituitary hormone loss in 5 to 15 percent, meningitis under 1 percent, catastrophic carotid injury well under 1 percent, and nasal crusting and reduced smell for the first six to twelve weeks. Visual worsening is rare — most patients see their visual fields improve.
-
How much does it cost privately in the UK?
Roughly £24,000 to £38,000 for a non-functioning macroadenoma, rising to £26,000 to £45,000 for functioning tumours where the case is longer and the follow-up is more complex. Urgent apoplexy decompression sits at £28,000 to £48,000. We come back with a firm figure across two or three UK skull-base teams within a few working days.
Related procedures
Looking for something else?
Nearby in the library